コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ance to extended-spectrum cephalosporins and aztreonam.
2 ance to expanded-spectrum cephalosporins and aztreonam.
3 s, particularly in cell filaments induced by aztreonam.
4 atalytic efficiency for both ceftazidime and aztreonam.
5 cephalosporin ceftazidime and the monobactam aztreonam.
6 delafloxacin to be comparable to vancomycin/aztreonam.
7 oc analysis of a randomized trial of inhaled aztreonam.
8 t compared ceftobiprole with vancomycin plus aztreonam.
9 be treated with cefuroxime, ceftriaxone, and aztreonam.
10 or, cefadroxil, cefuroxime, ceftriaxone, and aztreonam.
11 1.2% and an absence of cross-reactivity with aztreonam.
12 tment by combining ceftazidime-avibactam and aztreonam.
13 dime, cefotaxime, cefepime, cefpodoxime, and aztreonam.
14 rolyze a third-generation lactam antibiotic, aztreonam.
15 ance to extended-spectrum cephalosporins and aztreonam.
16 (62.7%) received ceftazidime-avibactam plus aztreonam, 33 (9.6%) received cefiderocol-containing reg
17 ce) rates were 47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 an
18 w breakpoints and standard concentrations of aztreonam (78), ceftazidime (79), ceftriaxone (83), or c
19 ent detected in parentheses): DD method with aztreonam (95), ceftazidime (79), ceftriaxone (88), or c
20 incidence of AEs between DLX and vancomycin/aztreonam across two phase 3 ABSSSI studies in order to
21 xone, cefotaxime, ceftazidime, cefepime, and aztreonam agar dilution MIC determination; ESBL screenin
22 2%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems), leading to consistent tre
24 ce phenotyping of the beta-lactams compound, aztreonam, amoxicillin/clavulanic acid, cefoxitin, cefta
25 ort ESBL-producing organisms as resistant to aztreonam and all cephalosporins (with the exception of
27 rthermore, we discovered that the monobactam aztreonam and BAL29880, a new beta-lactamase inhibitor o
28 These data indicate the tolerability of both aztreonam and carbapenems in penicillin-allergic subject
30 displayed negative skin test results to both aztreonam and carbapenems; 211 accepted challenges and t
31 penicillin reagent underwent skin tests with aztreonam and carbapenems; subjects with negative result
32 rganisms have added combination therapy with aztreonam and ceftazidime-avibactam, using ceftazidime-a
36 ess cross-reactivity with cephalosporins and aztreonam and the tolerability of such alternative beta-
37 is gene, which resulted in susceptibility to aztreonam and third- and fourth-generation cephalosporin
41 iving prophylaxis with ampicillin-sulbactam, aztreonam and vancomycin, or tigecycline (P = 0.61).
43 four antibiotics (tobramycin, ciprofloxacin, aztreonam, and imipenem), indicating that this has poten
46 chanisms to third-generation cephalosporins, aztreonam, and piperacillin-tazobactam seen across U.S.
47 conjugates with benzyl penicillin, imipenem, aztreonam, and the siderophore-conjugated monocarbam MC-
48 nical efficacy of ceftazidime/avibactam plus aztreonam as combination therapy for S. maltophilia infe
49 ith the extended-spectrum cephalosporins and aztreonam as resistant as suggested by current National
50 ion between NalD mutations and resistance to aztreonam-as well as resistance to other antibiotics-acr
51 t intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investiga
52 the in vitro activity of the combination of aztreonam (ATM) and ceftazidime-avibactam (CZA) to guide
53 vitro data support the use of combination of aztreonam (ATM) with ceftazidime-avibactam (CAZ-AVI), bu
55 atory testing options for the combination of aztreonam-avibactam are limited to broth microdilution (
56 Here, we report our internal validation for aztreonam-avibactam AST by reference broth microdilution
60 ntimicrobial susceptibility testing (AST) of aztreonam-avibactam is not commercially available; thus,
62 that the use of gradient strip diffusion for aztreonam-avibactam MIC determination in MBL-producing E
63 ile there are no established breakpoints for aztreonam-avibactam, category agreement (CA) for patient
69 this study, we evaluated the performance of aztreonam/avibactam gradient strips on 103 MBL-producing
70 ticles accumulated in cells increases as the aztreonam (AZT) concentration increases and as incubatio
76 0.5%) using the CLSI breakpoints (2 each for aztreonam, cefepime, and ceftriaxone, and 1 for cefazoli
77 stems when five-broad spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperaci
79 s increased for five antibiotics (5 to 406%)-aztreonam, cefpodoxime, ciprofloxacin, levofloxacin, ofl
80 welve tested antibiotics, with resistance to aztreonam, cefradine and gentamicin exhibiting a signifi
81 ) was exposed to the clinical combination of aztreonam + ceftazidime/avibactam (ATM/CAZ/AVI) to overc
82 cteriaceae were tested for susceptibility to aztreonam, ceftazidime, and meropenem; Enterobacteriacea
83 onotherapy was non-inferior to IV vancomycin/aztreonam combination therapy and was well tolerated in
84 lysis showed that ceftazidime-avibactam plus aztreonam, compared with colistin, was independently ass
85 red to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favor
86 the combination of ceftazidime-avibactam and aztreonam demonstrated expansion of the zone of inhibiti
88 per readings for ciprofloxacin, norfloxacin, aztreonam, erythromycin, clindamycin, and trimethoprim-s
90 ts (ceftriaxone for CABP and vancomycin plus aztreonam for ABSSSIs) at both a standard test of cure a
91 We aimed to assess safety and efficacy of aztreonam for inhalation solution (AZLI) in patients wit
93 The well-known affinity of the monobactam aztreonam for P. aeruginosa PBP3 is due to a distinct hy
95 cally important difference was higher in the aztreonam group at Week 4 (63% vs. 37%; P = 0.01) and at
96 and 88.1% in the ceftobiprole and vancomycin/aztreonam groups, respectively, and noninferiority was d
98 the beta-lactam antibiotics (median values: aztreonam, >128 microg/ml versus 4 microg/ml; ceftazidim
102 erococcosel broth (containing vancomycin and aztreonam) identified 88% and may be preferred over othe
104 ance to extended-spectrum cephalosporins and aztreonam in addition to cephamycins, such as cefoxitin.
105 penicillins and cefuroxime, ceftriaxone, and aztreonam in all subjects with T cell-mediated hypersens
106 ycin (IRR 7.6; 95% CI [2.2, 32.4]; p=0.001), aztreonam in HCT (IRR 9.7; 95% CI [3.3, 35.0]; p<0.001),
107 (IRR, 7.6 [95% CI, 2.2-32.4]; P = .001), and aztreonam in HCT (IRR, 9.7 [95% CI, 3.3-35.0]; P < .001)
108 the possibility of using cephalosporins and aztreonam in subjects with documented delayed hypersensi
109 Delafloxacin was comparable to vancomycin/aztreonam in the eradication of MRSA, at 98.1% versus 98
110 at ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early
111 esistant mutants hyperproduce L1, but retain aztreonam/inhibitor susceptibility because aztreonam is
113 mined that alternation of ciprofloxacin with aztreonam is more efficient than ciprofloxacin-tobramyci
115 r S. maltophilia infections and confirm that aztreonam-like beta-lactams plus nonclassical beta-lacta
116 CI, -0.44 to 0.13), whereas users of inhaled aztreonam lysine and azithromycin experienced a mean 0.4
117 While MBLs do not hydrolyze monobactams (aztreonam), many MBL-producing organisms are resistant t
118 ratory Symptoms Score at Week 4) in favor of aztreonam (mean difference of 9.7 points; 95% confidence
119 07-fold higher permeability as compared with aztreonam (mean permeability coefficient of 17,200 nm/s)
122 cohorts using chronic inhaled tobramycin or aztreonam.Methods: This retrospective cohort study used
123 rains producing ESBLs, while ceftriaxone and aztreonam MICs separated low-level K1 from high-level K1
125 oad-spectrum prophylaxis with vancomycin and aztreonam (n = 40), piperacillin-tazobactam (n = 11), ca
126 plates that contained vancomycin and either aztreonam or ceftazidime were used as the selective medi
127 we show that the combinations ciprofloxacin-aztreonam or ciprofloxacin-tobramycin are the most effec
128 Acylation of PBP3 with cephalexin, but not aztreonam or piperacillin, appeared to be stimulated by
129 acteremic patient with sequential failure of aztreonam plus ceftazidime-avibactam followed by cefider
130 mented CLSI disk test (CLSI plus BA), and an aztreonam plus clavulanate disk test (ATM plus CA).
131 us ceftriaxone, cefepime, ciprofloxacin, and aztreonam promoted increased VRE density to a lesser deg
132 cy for ceftazidime but a 3-fold increase for aztreonam relative to the G238S:E240K double mutant.
133 prediction of ceftriaxone, ceftazidime, and aztreonam resistance and 73% (range, 25 to 90%) sensitiv
134 f the MexAB-OprM efflux system-which lead to aztreonam resistance but, surprisingly, had no fitness c
135 to detect extended-spectrum cephalosporin or aztreonam resistance in any of the ESBL- or AmpC-produci
136 hways and membrane transport concurrent with aztreonam resistance, which may explain the lack of a fi
138 (94.3%), for ceftaroline and vancomycin plus aztreonam, respectively, and did not differ from those a
139 activated by the beta-lactams mecillinam and aztreonam, respectively, several mutants did not lyse bu
140 tion of extended-spectrum cephalosporins and aztreonam results from the susceptible to the resistant
141 ction, can gain resistance to the antibiotic aztreonam through a mutation in NalD, a transcriptional
142 any MBL-producing organisms are resistant to aztreonam through alternate mechanisms, leaving cefidero
143 obacter cloacae versus ampicillin-sulbactam, aztreonam, ticarcillin, and ticarcillin-clavulanate and
144 hose who especially require cephalosporin or aztreonam treatment, however, we recommend pretreatment
145 resistant to carbapenems but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquin
146 of ceftazidime, cefotaxime, ceftriaxone, or aztreonam was >or=2 microg/ml or the MIC of cefpodoxime
147 idime-avibactam alone or in combination with aztreonam was associated with a reduction in mortality.
148 idime-avibactam alone or in combination with aztreonam was associated with decreased 30-day mortality
149 n in differentiating between ceftazidime and aztreonam was further investigated by kinetic analysis o
150 Improvement of quality of life with inhaled aztreonam was only evident in patients with high bacteri
151 me, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated with bacteremia due to ESBL-pr